Business
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal
Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024AVENTURA, Fla. and SARASOTA, Fla., Dec. 11, 2023 /PRNewswire/ -- NAYA Biosciences Inc. (\"NAYA\"), a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, today announced that new data for its CD38-targeted Flex-NK™ Bispecific Antibody (NY-338, formerly CYT-338) for the treatment of Multiple Myeloma (MM) was published as an abstract in the 2023 American Society of Hematology's (ASH) meeting supplement of Blood, in the \"Multiple Myeloma: Prospective Therapeutic Trials\" section.\n\n \n \n \n \n \n \n\n \n\"NAYA is building a portfolio of differentiated clinical-stage oncology therapeutics, starting with two FLEX-NK™ bispecific antibodies acquired from Cytovia Therapeutics,\" commented NAYA CEO Dr. Daniel Teper. \"We are excited about this new data for our CD38-targeted antibody, which aims to address limitations with the current standard-of-care and offer new options for multiple myeloma patients.\"\n\"The synergistic engagement of NK cells through NKp46 greatly enhances the immunotherapeutic effects of FLEX-NK™ bispecific antibodies, reducing NK cell fratricide, maintaining NK cell levels, and enhancing potency including reversal of NK cell dysfunction,\" added Ola Landgren, MD, PhD, co-author of the abstract and Professor of Medicine, Chief of the Myeloma Division, and Leader of the Experimental Therapeutics Program at the University of Miami's Sylvester Comprehensive Cancer Center. \"The data supports initiation of clinical trials to evaluate this promising new therapy and makes it a potential best-in-class anti-CD38 therapeutic for multiple myeloma.\"\nDespite the clinical success of the first anti-CD38 targeted monoclonal antibody, daratumumab, approved for the treatment of multiple myeloma (MM), significant challenges remain such as CD38 antigen loss/internalization and/or natural killer (NK) ce...